Summit Therapeutics (SMMT) Q1 2025 earnings summary

Executive summary

• Ivonescimab, a bispecific antibody targeting PD-1 and VEGF, achieved significant regulatory milestones, including expanded approval in China for first-line advanced NSCLC with positive PD-L1 expression, based on Harmony-II trial interim OS HR=0.777.

• Multiple Phase III trials are completed or ongoing globally and in China, including HARMONI, HARMONI-3, HARMONI-6, and HARMONI-7, with topline results from the global HARMONI trial expected mid-2025.

• HARMONI-6 Phase III trial met its primary endpoint, showing statistically significant and clinically meaningful PFS improvement for ivonescimab plus chemotherapy in advanced squamous NSCLC, with no new safety signals identified.

• Collaborations with MD Anderson and Pfizer are advancing, with new trials enrolling in additional solid tumor settings and over 30 investigator-sponsored trials ongoing.

• Appointment of a new Chief Commercial Officer and key hires in market access, marketing, and sales to support commercial launch.

Financial highlights

• Ended Q1 2025 with cash and short-term investments of $361.3 million.

• GAAP R&D expenses for Q1 2025 were $51.2 million, flat sequentially; non-GAAP R&D expenses were $47.1 million.

• GAAP G&A expenses increased to $15.6 million in Q1 2025, mainly due to higher compensation and professional services; non-GAAP G&A expenses were $8.6 million.

• GAAP net loss was $62.9 million ($0.09/share) in Q1 2025; non-GAAP net loss was $51.8 million ($0.07/share).

• No debt as of March 31, 2025, with all promissory notes repaid by October 2024.

Outlook and guidance

• Topline data from the global HARMONI Phase III trial in EGFR-mutated NSCLC expected mid-2025, with both PFS and OS endpoints.

• Additional clinical trial initiations, data readouts, and pipeline expansion are anticipated in 2025, including Pfizer collaboration trials and expansion beyond lung cancer.

• Sufficient cash and investments to fund operations for at least the next 12 months; additional capital may be needed for milestone payments and future operations.

• Preparations underway for the first potential commercial launch of ivonescimab.